After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...

The S&P 1500 Health Care Index gained 1.9% in September, underperforming the S&P 500, which advanced 3.7%. Read more here.

VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the company tries to turn around a run ...

(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic ...

Argenx (ARGX) announced that Health Canada has issued a notice of compliance authorizing Vyvgart as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating ...

Antibodies to aquaporin-4 (also known as AQP4-Ab or NMO-IgG) are sensitive and highly specific serum markers of autoimmune neuromyelitis optica (NMO). Second-generation recombinant diagnostic assays ...

A 35 year-old man with multiple sclerosis had a history of 1-2 attacks every year. Multiple Sclerosis (MS): Flair axial MRIs. Note the numerous demyelinating lesions in multiple areas of the white ...

The nerve damage that results in neuropathy (also known as peripheral neuropathy) not only causes symptoms such as pain, numbness, tingling, burning sensations, muscle weakness, incontinence, or ...